Effects of different anti-osteoporosis medications on re-fracture risk, bone mineral density, and functional recovery following hip fragility fracture surgery: a systematic review and network meta-analysis.

What was studied

This review compared drugs for bone loss after surgery for a fragile hip fracture. These patients face a high risk of a new fracture. They are also at risk of poor recovery. The team searched several databases for work from January 1, 2015. The search ran up to April 15, 2026. Randomised and non-randomised studies were included. Network meta-analyses were done. Outcomes were new fractures, hip bone density, Harris Hip Score and VAS scores. GRADE rated how sure the evidence was. The review covered 2,414 patients.

What they found

Effects varied by outcome and by follow-up time. No drug was shown to be better across the board. Some rankings gave favourable signals. ZOL and DEN looked favourable for new hip fractures at 12 months. ZOL and ALN looked favourable for any new fracture at 12 months. TPTD and DEN looked favourable for any new fracture at 24 months. The authors treat these rankings as descriptive summaries. Bone density rankings changed with the way results were reported. No clear gaps were found for bone density, Harris Hip Score or VAS scores. Checks that left out one study at a time were broadly stable. GRADE ratings showed limited certainty across outcomes.

What it means for patients

The authors say drug effects depended on the outcome and the time point. They say no drug was shown to be better overall. ZOL, DEN and ALN gave more favourable signals for some early fracture outcomes. TPTD gave a more favourable pattern for longer-term bone mass. They call the findings signals in context, not advice on treatment.

Why it is not certain yet

Certainty was limited across outcomes, and most evidence was of low certainty. The rankings are only descriptive summaries. Bone density rankings changed with the reporting format. A review can only be as good as the studies in it.

Source

Effects of different anti-osteoporosis medications on re-fracture risk, bone mineral density, and functional recovery following hip fragility fracture surgery: a systematic review and network meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.